Wall Street brokerages expect that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will post $4.54 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Teva Pharmaceutical Industries’ earnings, with the lowest sales estimate coming in at $4.43 billion and the highest estimate coming in at $4.76 billion. Teva Pharmaceutical Industries posted sales of $5.46 billion in the same quarter last year, which would indicate a negative year over year growth rate of 16.8%. The business is scheduled to report its next quarterly earnings report before the market opens on Wednesday, February 13th.

According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full year sales of $18.86 billion for the current year, with estimates ranging from $18.73 billion to $19.05 billion. For the next year, analysts expect that the firm will post sales of $17.88 billion, with estimates ranging from $17.42 billion to $18.09 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Teva Pharmaceutical Industries.

A number of equities analysts recently commented on TEVA shares. UBS Group raised Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating in a research note on Wednesday, January 23rd. Bank of America raised Teva Pharmaceutical Industries from an “underperform” rating to a “buy” rating and set a $16.12 price target for the company in a research note on Thursday, January 3rd. Piper Jaffray Companies raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and increased their price target for the company from $15.00 to $16.00 in a research note on Wednesday, January 23rd. Morgan Stanley raised Teva Pharmaceutical Industries from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $20.00 to $27.00 in a research note on Monday, November 5th. Finally, Zacks Investment Research lowered Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research note on Monday, January 21st. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $22.98.

Teva Pharmaceutical Industries stock traded up $0.60 during midday trading on Wednesday, reaching $18.82. 8,452,711 shares of the stock traded hands, compared to its average volume of 8,351,525. Teva Pharmaceutical Industries has a 12 month low of $14.59 and a 12 month high of $25.96. The firm has a market cap of $18.53 billion, a PE ratio of 4.79, a PEG ratio of 5.83 and a beta of 1.46. The company has a current ratio of 0.94, a quick ratio of 0.61 and a debt-to-equity ratio of 1.75.

In other news, VP Hafrun Fridriksdottir sold 1,643 shares of the firm’s stock in a transaction that occurred on Wednesday, January 2nd. The stock was sold at an average price of $15.70, for a total value of $25,795.10. Following the completion of the sale, the vice president now directly owns 13,469 shares of the company’s stock, valued at approximately $211,463.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.43% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of the stock. FMR LLC increased its holdings in Teva Pharmaceutical Industries by 19.1% during the 3rd quarter. FMR LLC now owns 24,481,936 shares of the company’s stock worth $527,341,000 after purchasing an additional 3,921,785 shares during the period. Polaris Capital Management LLC increased its holdings in Teva Pharmaceutical Industries by 4.4% during the 4th quarter. Polaris Capital Management LLC now owns 10,342,980 shares of the company’s stock worth $159,489,000 after purchasing an additional 431,942 shares during the period. Alliancebernstein L.P. increased its holdings in Teva Pharmaceutical Industries by 32.0% during the 3rd quarter. Alliancebernstein L.P. now owns 9,454,839 shares of the company’s stock worth $203,657,000 after purchasing an additional 2,291,171 shares during the period. TIAA CREF Investment Management LLC increased its holdings in Teva Pharmaceutical Industries by 4.4% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 6,335,449 shares of the company’s stock worth $136,466,000 after purchasing an additional 264,693 shares during the period. Finally, Harel Insurance Investments & Financial Services Ltd. increased its holdings in Teva Pharmaceutical Industries by 99.9% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 5,715,499 shares of the company’s stock worth $88,133,000 after purchasing an additional 2,855,802 shares during the period. 62.11% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: Short Selling

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.